Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSEN1 | P49768 | 17/20 | 0.47 |
| ▸ | PSEN2 | P49810 | 17/20 | 0.47 |
| ▸ | APH1B | Q8WW43 | 17/20 | 0.47 |
| ▸ | NCSTN | Q92542 | 17/20 | 0.47 |
| ▸ | APH1A | Q96BI3 | 17/20 | 0.47 |
| ▸ | PSENEN | Q9NZ42 | 17/20 | 0.47 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31114335 | 0.93 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL31518743 | 0.93 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL31518747 | 0.93 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL31312605 | 0.91 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30892073 | 0.91 | PSEN1 (0.47) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30543486 | 0.91 | OPRM1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30662558 | 0.90 | OPRM1 (0.43) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL38651798 | 0.90 | OPRM1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL38651875 | 0.90 | OPRM1 (0.46) | PSEN1PSEN2APH1BNCSTNAPH1A | |
| SCHEMBL30852879 | 0.90 | OPRM1 (0.44) | PSEN1PSEN2APH1BNCSTNAPH1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250368601-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE | VERANOVA L P (US) | 2025-12-04 | — | — | US | disclosed |
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-10-22 | — | — | US | disclosed |
| CN-116096719-A | Pyridazinylamino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-09 | — | — | CN | disclosed |
| CN-116075307-A | Pyridooxazine amino derivatives as ALK5 inhibitors | 奇斯药制品公司 | 2023-05-05 | — | — | CN | disclosed |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2022-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250368601-A1 | PROCESS FOR THE PREPARATION OF LISDEXAMFETAMINE | PHYKPL, DLST, COMT | PSEN1 1103/4885PSEN2 1823/4885APH1B 1859/4885 |
| US-20220135638-A1 | GIP RECEPTOR AGONIST PEPTIDE COMPOUNDS AND USES THEREOF | GIPR, GLP1R, VIPR1 | PSEN1 3808/4885PSEN2 4515/4885APH1B 1296/4885 |
| US-12122815-B2 | GIP receptor agonist peptide compounds and uses thereof | GIPR, GLP1R, GPR119 | PSEN1 4158/4885PSEN2 4687/4885APH1B 1521/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.